Search Results - "Gross, Mitchell E"

Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial by Dawson, Jacqueline K, Dorff, Tanya B, Todd Schroeder, E, Lane, Christianne J, Gross, Mitchell E, Dieli-Conwright, Christina M

“…Prostate cancer patients on androgen deprivation therapy (ADT) experience adverse effects such as lean mass loss, known as sarcopenia, fat gain, and changes in…”
Get full text

Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells by Dago, Angel E, Stepansky, Asya, Carlsson, Anders, Luttgen, Madelyn, Kendall, Jude, Baslan, Timour, Kolatkar, Anand, Wigler, Michael, Bethel, Kelly, Gross, Mitchell E, Hicks, James, Kuhn, Peter

“…Timely characterization of a cancer's evolution is required to predict treatment efficacy and to detect resistance early. High content analysis of single…”
Get full text

Detection of Androgen Receptor Mutations in Circulating Tumor Cells in Castration-Resistant Prostate Cancer by YUQIU JIANG, PALMA, John F, AGUS, David B, YIXIN WANG, GROSS, Mitchell E

“…Coding mutations in the AR (androgen receptor) gene have been identified in tissue samples from patients with advanced prostate cancer and represent a possible…”
Get full text

Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA) by Patsch, Katherin, Matasci, Naim, Soundararajan, Anjana, Diaz, Patricia, Agus, David B, Ruderman, Daniel, Gross, Mitchell E

“…Cell-free DNA (cfDNA) is an attractive cancer biomarker, as it is thought to reflect a component of the underlying genetic makeup of the tumor and is readily…”
Get full text

Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer by Jadvar, Hossein, Desai, Bhushan, Ji, Lingyun, Conti, Peter S, Dorff, Tanya B, Groshen, Susan G, Gross, Mitchell E, Pinski, Jacek K, Quinn, David I

“…PURPOSEThis study aimed to perform a prospective evaluation of F-NaF and F-FDG PET/CT in the detection of occult metastatic disease in men with prostate cancer…”
Get full text

Automated analysis of co-localized protein expression in histologic sections of prostate cancer by Tennill, Thomas A, Gross, Mitchell E, Frieboes, Hermann B

“…An automated approach based on routinely-processed, whole-slide immunohistochemistry (IHC) was implemented to study co-localized protein expression in tissue…”
Get full text

Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression by Patel, Nitin, Itakura, Tatsuo, Jeong, Shinwu, Liao, Chun-Peng, Roy-Burman, Pradip, Zandi, Ebrahim, Groshen, Susan, Pinski, Jacek, Coetzee, Gerhard A, Gross, Mitchell E, Fini, M Elizabeth

“…Prostate cancer (PCa) is the second-leading cause of cancer-related mortality, after lung cancer, in men from developed countries. In its early stages, primary…”
Get full text

Effect of Periodized Resistance Training on Skeletal Muscle During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Trial by Dawson, Jacqueline K., Dorff, Tanya B., Tuzon, Creighton, Rice, Judd C., Schroeder, Edward Todd, Lane, Christianne J., Gross, Mitchell E., Dieli-Conwright, Christina M.

“…Purpose: Prostate cancer survivors (PCS) receive androgen deprivation therapy (ADT) as treatment for recurrent cancer, yet ADT is associated with loss of…”
Get full text

Immune biomarkers associated with COVID-19 disease severity in an urban, hospitalized population by Chambliss, Allison B., Aljehani, Mayada, Tran, Brian, Chen, Xingyao, Elton, Elizabeth, Garri, Carolina, Ung, Nolan, Matasci, Naim, Gross, Mitchell E.

“…We sought to identify immune biomarkers associated with severe Coronavirus disease 2019 (COVID-19) in patients admitted to a large urban hospital during the…”
Get full text

Salvage ablative therapy in prostate cancer: International multidisciplinary consensus on trial design by van den Bos, Willemien, M.D, Muller, Berrend G., M.D, de Bruin, Daniel M., Ph.D, de Castro Abreu, Andre Luis, M.D, Chaussy, Christian, M.D, Coleman, Jonathan A., M.D, Finelli, Antonio, M.D, Gill, Inderbir S., M.D, Gross, Mitchell E., M.D, Jenniskens, Sjoerd F.M., M.D., P.h.D, Kahmann, Frank, M.D, Laguna-Pes, M. Pilar, M.D., P.h.D, Rastinehad, Ardeshir R., M.D, Simmons, Lucy A., M.D, Sulser, Tullio, M.D, Villers, Arnauld, M.D., P.h.D, Ward, John F., M.D, de la Rosette, Jean J.M.C.H., M.D., P.h.D

“…Abstract Introduction Salvage ablative therapy (SAT) has been developed as a form of localized treatment for localized recurrence of prostate cancers following…”
Get full text

CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation by Trac, Noah, Chen, Leng-Ying, Zhang, Ailin, Liao, Chun-Peng, Poon, Christopher, Wang, Jonathan, Ando, Yuta, Joo, Johan, Garri, Carolina, Shen, Keyue, Kani, Kian, Gross, Mitchell E., Chung, Eun Ji

“…Signaling between the CC chemokine receptor 2 (CCR2) with its ligand, monocyte chemoattractant protein-1 (MCP-1) promotes cancer progression by directly…”
Get full text

Effect of Monoamine oxidase A (MAOA) inhibitors on androgen‐sensitive and castration‐resistant prostate cancer cells by Gaur, Shikha, Gross, Mitchell E., Liao, Chun‐Peng, Qian, Bin, Shih, Jean C.

“…Background Monoamine oxidase A (MAOA) is best known for its role in neuro‐transmitter regulation. Monoamine oxidase inhibitors are used to treat atypical…”
Get full text

Focal Cryotherapy for Clinically Unilateral, Low-Intermediate Risk Prostate Cancer in 73 Men with a Median Follow-Up of 3.7 Years by Bahn, Duke, de Castro Abreu, Andre Luis, Gill, Inderbir S, Hung, Andrew J, Silverman, Paul, Gross, Mitchell E, Lieskovsky, Gary, Ukimura, Osamu

“…Abstract Background Evolution of cryotherapy for prostate cancer is likely to result in parenchyma-sparing modifications adjacent to the urethra and…”
Get full text

Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate by Liao, Chun-Peng, Lin, Tzu-Ping, Li, Pei-Chuan, Geary, Lauren A., Chen, Kevin, Vaikari, Vijaya Pooja, Wu, Jason Boyang, Lin, Chi-Hung, Gross, Mitchell E., Shih, Jean C.

“…Monoamine oxidase A (MAOA) is a mitochondrial enzyme, which degrades monoamine neurotransmitters and dietary amines and produces H 2 O 2 . Recent studies have…”
Get full text

Blood-based gene expression profiling in castrate-resistant prostate cancer by Gross, Mitchell E

“…Castrate-resistant prostate cancer (CRPC), the most life-threatening form of prostate cancer, has recently been the focus of many successful new treatments…”
Get full text

Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells by Liao, Chun-Peng, Chen, Leng-Ying, Luethy, Andrea, Kim, Youngsoo, Kani, Kian, MacLeod, A Robert, Gross, Mitchell E

“…Androgen receptor (AR) regulation pathways are essential for supporting the growth and survival of prostate cancer cells. Recently, sub-populations of prostate…”
Get full text

Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer by Gross, Mitchell E., Agus, David B., Dorff, Tanya B., Pinski, Jacek K., Quinn, David I., Castellanos, Olga, Gilmore, Patrick, Shih, Jean C.

“…Purpose Monoamine oxidase A (MAOA) influences prostate cancer growth and metastasis in pre-clinical models. We examined effects of phenelzine (a monoamine…”
Get full text

Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis by Tiemann, Katrin, Garri, Carolina, Lee, Sang Bok, Malihi, Paymaneh D., Park, Mincheol, Alvarez, Ruth M., Yap, Li Peng, Mallick, Parag, Katz, Jonathan E., Gross, Mitchell E., Kani, Kian

“…Anterior gradient 2 (AGR2) is a member of the protein disulfide isomerase (PDI) family, which plays a role in the regulation of protein homeostasis and the…”
Get full text

Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration by Jacobs, Michaela R., Olivero, Jennifer E., Ok Choi, Hyun, Liao, Chun-Peng, Kashemirov, Boris A., Katz, Jonathan E., Gross, Mitchell E., McKenna, Charles E.

“…[Display omitted] •Clorgyline is an irreversible monoamine oxidase A inhibitor used clinically as an antidepressant.•Previous studies show that clorgyline and…”
Get full text

Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors by Eisenberg, Stacy A., Kurita, Keiko, Taylor-Ford, Megan, Agus, David B., Gross, Mitchell E., Meyerowitz, Beth E.

“…Objective Prostate cancer survivors have reported cognitive complaints following treatment, and these difficulties may be associated with survivors' ongoing…”
Get full text